Searchable abstracts of presentations at key conferences in endocrinology

ea0098c55 | Clinical – Surgery/Applied Pathology | NANETS2023

Association of long-term PPI use with low-risk gastric neuroendocrine tumor

Al-Toubah MPH Taymeyah , Pelle MD Eleonora , Strosberg MD Jonathan

Background: Gastric neuroendocrine tumors are rare neoplasms, comprising approximately 2% of all gastric tumors, and develop from enterochromaffin-like (ECL) cells in the gastric mucosa. Type I and II develop due to hypergastrinemia and ECL cell hyperplasia; type III typically occur sporadically, tend to be more aggressive, present metastatically in > 50% of cases, have normal fasting gastrin levels, and vary histopathologically from well- to poorly differentiated tumors. ...

ea0089c8 | Clinical – Chemo/SSA/Biologics | NANETS2022

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-Differentiated Neuroendocrine Tumors

Al-Toubah, MPH Taymeyah , Morse, MD Brian , Haider, MD Mintallah , Valone, PA Tiffany , Strosberg, MD Jonathan

Background: Immune checkpoint inhibitors have not been shown to be active in well-differentiated NETs, with response rates <5%. Lenvatinib is a multitargeted TKI which targets VEGF and FGF receptors and has been reported to be effective in pancreatic and gastrointestinal NETs (40% and 18.5% ORR, respectively). The combination of antiangiogenic and checkpoint inhibitor therapies can be synergistic in other cancers. We therefore evaluated the combination of lenvatinib and pe...

ea0089c10 | Clinical – Chemo/SSA/Biologics | NANETS2022

ACTH-secreting Pancreatic Neuroendocrine Neoplasms: A Case-Series

Pelle, MD Eleonora , Al-Toubah, MPH Taymeyah , Hallanger-Johnson, MD Julie , Strosberg, MD Jonathan

Background: Pancreatic neuroendocrine neoplasms rarely secrete ACTH resulting in ectopic Cushing’s syndrome. Data are limited to case reports and very small series.Methods: Cases of ectopic Cushing’s syndrome were identified from a database of pancreatic NEN seen at the Moffitt Cancer Center between 1/2008 and 4/2022. Tumor characteristics, clinical signs and symptoms, therapies and outcomes were evaluated.Results: 13 pat...

ea0089c23 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Somatostatin receptor expression in lung neuroendocrine tumors: an analysis of Dotatate PET scans

Al-Toubah, MPH Taymeyah , Pelle, MD Eleonora , El-Haddad, MD Ghassan , Strosberg, MD Jonathan

Background: Somatostatin receptor (SSTR) expression in metastatic lung neuroendocrine (carcinoid) tumors has not been well-characterized using modern positron emission tomography (PET) imaging. Understanding degree and uniformity of SSTR expression is important to establish the role of SSTR targeted treatments, including peptide receptor radiotherapy (PRRT), in lung NETs.Methods: Retrospective review of medical records and imaging studies of patients wit...

ea0098c29 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Small bowel ischemia in patients with midgut neuroendocrine tumors after treatment with 177Lutetium-Dotatate

Pelle, MD Eleonora , Al-Toubah, MPH Taymeyah , El-Haddad, MD Ghassan , Strosberg, MD Jonathan

Background: 177Lutetium (Lu)-Dotatate is a safe and well tolerated treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described. We investigated the potential for intestinal ischemia in 177Lu-Dotatate treated patients.Methods:...

ea0089o1 | Other | NANETS2022

Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) – A Systematic Review and Meta-Analysis

Das, MD, MSCI Satya , Phillips, MSPH Sharon , M Lebeck Lee, MD Cody , Agarwal, MD, MSCI Rajiv , Bergsland, MD Emily , Strosberg, MD Jonathan , A. Chan, MD, MPH Jennifer , LaFerriere, MLIS Heather , A. Ramirez, DO Robert , Berlin, MD Jordan , Arvind Dasari, MD, MS and

Background: Although anti-VEGF RTKIs have been tested in patients with NETs over the last 2 decades, no study to date has benchmarked efficacy and toxicity of these drugs in this patient population.Methods: A literature search was performed to identify all phase II and phase III studies of anti-VEGF RTKIs in patients with NETs published between January 1, 2000 – July 31, 2021. Major trial databases (e.g. Medline, EMBASE, Cumulative Index of Nursing ...